We have located links that may give you full text access.
CASE REPORTS
JOURNAL ARTICLE
Changing indications for the Ross operation.
Seminars in Thoracic and Cardiovascular Surgery 1996 October
The first Ross operation in Copenhagen was performed in 1992, and from the beginning of the series, which now numbers 80 patients, the underlying philosophy has been based on our belief that the autograft/Ross operation possesses a number of important and unique advantages compared with other alternatives, particularly for patients with complicated aortic valve disease in which alternative treatments are not satisfactory. The series includes patients of 6 weeks to 71 years of age, many with complicating conditions (endocarditis, 24 patients [native valve, 15; prosthetic valve, 9; advanced 17; active, 15; healed, 9], prosthetic valve dysfunction, 4; small aortic root, 2; ascending aortic aneurysm, 5; ventricular septum defect, 2; mitral valve disease, 7; tricuspid valve disease, 2; rheumatic heart disease, 7; aortic annular dilatation, 2; coronary artery disease, 4; extreme obesity, 1; severely reduced left ventricular function, 7; and previous heart surgery, 28). Mortality is low: hospital mortality, 3 patients (3.75%); late mortality, 1 patient (1.25%). Three patients have required reoperation, however; 1 because of autograft insufficiency and 2 because of pulmonary homograft stenosis, but autograft function is good in 73 (< or = 1+) and acceptable (< or = 2+) in 3 patients, and seems to be stable at follow-up. All in all, the early results are encouraging. We are particularly enthusiastic about the Ross operation for patients with complicated aortic valve pathology such as endocarditis, the small aortic root, combined valvular and subvalvular stenosis, and we believe that the Ross operation may be the best operation for these patients.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
The Effect of Albumin Administration in Critically Ill Patients: A Retrospective Single-Center Analysis.Critical Care Medicine 2024 Februrary 8
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app